Mithra Pharmaceuticals S.A.

AGM Information • Oct 5, 2018

NOTICE OF 2018 EXTRAORDINARY GENERAL MEETING REGARDING PROPOSED WARRANT PLAN

Liège, Belgium, 5 October 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women's Health, today announces its intention to hold an Extraordinary General Meeting ("EGM") on the 5 November 2018 at 11:00 am in Flémalle, 57 rue de l'Expansion (Belgium). The meeting will consider a new warrant plan whereby a maximum of 1,881,974 warrants would be issued, subject to shareholder approval.

The special reports prepared by the board of directors (in accordance with Articles 583, 596 and 598 of the Belgian Companies Code) and the Company's statutory auditor (in accordance with Articles 596 and 598 of the Belgian Companies Code) are available on Mithra's website. The notice for the EGM for shareholders, including details on how to participate in the meeting, is also available on the Company's website, investors.mithra.com

********

For more information, please contact:

Investor Relations & Press

François Fornieri (CEO): +32 4 349 28 22 Jean-Manuel Fontaine (PRO): +32 (0)476 96 54 59 investorrelations@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should",

REGULATED INFORMATION

and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com